

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CinPhloro Doses First Participant In Phase 2 Enviva Study Of CIN-103 For IBS-D
Details : CIN-103 (phloroglucinol) is a voltage-gated calcium channel blocker. It is being evaluated as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 22, 2024
Lead Product(s) : Phloroglucinol
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
